

# Dosimetric comparison of IMRT and VMAT treatment plans for breast cancer with 1-2 sentinel lymph node metastasis

K. Yao<sup>1#</sup>, M. Wang<sup>1#</sup>, C. Shi<sup>1</sup>, H. Wu<sup>1,2</sup>, J. Liu<sup>1</sup>, H. Yue<sup>1</sup>, R. Wang<sup>1\*</sup>, Y. Du<sup>1,2\*</sup>

<sup>1</sup>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing 100142, China

<sup>2</sup>Institute of Medical Technology, Peking University Health Science Center, Beijing, China

## ► Original article

## ABSTRACT

### \*Corresponding author:

Ruoxi Wang, Ph.D.,

Yi Du, Ph.D.,

E-mail: ruoxi.wang@pku.edu.cn  
yidu\_rt@163.com

Received: January 2025

Final revised: July 2025

Accepted: August 2025

Int. J. Radiat. Res., April 2026;  
24(2): 301-307

DOI: 10.61186/ijrr.24.2.1

**Keywords:** Breast Cancer, Sentinel Irradiation, Lymph Node Metastasis, Dosimetry, Radiotherapy.

# Kaining Yao and Meijiao Wang contributed equally to this work.

**Background:** To compare the dosimetry of Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) techniques for breast cancer patients with 1-2 sentinel lymph node metastases. **Materials and Methods:** A total of 90 breast cancer patients (left:33, right:57) receiving post-operative radiotherapy were retrospectively included. IMRT and VMAT treatment plans were designed for each patient with same prescriptions and dose-volume constraints. Key dose-volume histogram (DVH) metrics in target volumes and organs-at-risks (OARs) were analyzed and compared in groups. **Results:** Compared with IMRT, VMAT showed superior target coverage and dose conformity, particularly for planning target volume (PTV) and axillary levels 1-2 lymph nodes in both left- and right-sided cancers. For left-sided cases, VMAT significantly reduced mean dose (Dmean) to the heart and left coronary artery ( $p < 0.001$ ), with a 33% decrease in V40% for left coronary artery. For right-sided cases, VMAT showed a modest Dmean increase to these structures due to dose spillage, though all values remained within clinical constraints. Compared with IMRT, VMAT demonstrated superior dose sparing for the ipsilateral lung and humeral head. While both techniques achieved comparable dose coverage for axillary level 3 lymph nodes ( $p > 0.05$ ), VMAT required significantly fewer monitor units (MU) ( $p < 0.001$ ). **Conclusion:** The dosimetric analysis demonstrates VMAT's superiority over IMRT in breast cancer patients with 1-2 sentinel lymph node metastases, offering improved target coverage, enhanced organ sparing, and greater delivery efficiency.

## INTRODUCTION

Breast cancer is one of the most common female cancers all over the world <sup>(1)</sup>, and the systematic treatment of breast cancer typically involves surgery, chemotherapy, and radiotherapy. For patients receiving breast-conserving surgery but with 1-2 positive sentinel lymph node biopsy, a viable treatment option is adjuvant radiotherapy with axillary irradiation. For these patients, the target volume in radiotherapy includes the ipsilateral breast and the axillary lymph node region <sup>(2-6)</sup>.

The axillary lymph node region is anatomically composed of three sub-regions indexed as level 1, level 2, and level 3, respectively. The expanded and anatomically complex target volume poses challenges for treatment planning. Early studies <sup>(7,8)</sup> using 3D-conformal radiotherapy (3D-CRT) with tangential fields demonstrated adequate dose delivery to the primary breast target but insufficient coverage of axillary levels, as these regions were not defined as target volume in early planning protocols. Nitsche *et al.* <sup>(9)</sup> expanded the target volume definition to include axillary levels 1-3 to address these coverage gaps. They evaluated target dose coverage and organ-at-risk (OAR) exposure in tangential-field radiation.

Similarly, Alco *et al.* <sup>(10)</sup> adjusted the position of the multi-leaf collimator (MLC) in tangential fields to enhance the dose to axillary levels 1 and 2. While these strategies improved axillary coverage, they also inadvertently increased the dose of OARs.

With the advent of Volumetric Modulated Arc Therapy (VMAT), several studies have demonstrated improved conformity and uniformity in target volume coverage, along with enhanced OAR sparing <sup>(11-15)</sup>. Tuomas *et al.* showed that VMAT significantly reduced dose to the heart and ipsilateral lung in left-sided breast cancer patients <sup>(16)</sup>. Moreover, Mikel *et al.* found that tangential VMAT field arrangements were viable for patients with breast or chest wall involvement and internal mammary nodal disease <sup>(17)</sup>. Also, Boman *et al.* compared different radiation field arrangements, and their results showed that the split-arc VMAT technique offered dosimetric advantages for the target volumes, heart, and ipsilateral lung <sup>(18)</sup>. These findings indicated that utilizing multiple partial-arc fields in VMAT planning might have dosimetric advantages.

However, dosimetric studies on treatment techniques are rare for patients receiving axillary levels 1-2 radiation, and the optimal VMAT planning strategy still needs to be discovered. This study

evaluates partial-arc VMAT techniques with diverse field arrangements for breast cancer radiotherapy targeting axillary levels 1-2, comparing plan quality with conventional tangential IMRT.

## MATERIALS AND METHODS

### Cohort description

This work retrospectively enrolled 90 breast cancer patients receiving post-operative radiotherapy at Peking University Cancer Hospital between January 2018 and December 2023. The selection criteria were: 1) confirmation of breast cancer through pathology; 2) presence of 1-2 positive sentinel lymph nodes without lymph node dissection; 3) prescription with a simultaneous boost to the ipsilateral tumor bed. Over the cohort, 33 cases were left-sided breast cancer, and 57 were right-sided. Patients aged 30 - 73 (median = 49.5) had clinically staged T1-2N1M0, whose pathology diagnosis was invasive ductal carcinoma (IDC). This study was approved by the Institutional Review Board (IRB) of Peking University Cancer Hospital (Approval number: 2022YJZ100).

### Target delineation

Patients were immobilized using a breast board with thermoplastic mask. Simulation CT scans (5-mm slice thickness,  $0.7 \times 0.7$  mm resolution) were acquired for planning. Target volumes were contoured following ESTRO guidelines and institutional protocols (19), with all delineations reviewed by a senior physician panel prior to planning. Two clinical target volumes (CTV) were defined for each case:

CTV<sub>breast</sub>, encompassing the entire ipsilateral breast and axillary levels 1 and 2, while level 3 was considered an OAR.

CTV<sub>boost</sub>, including the breast tumor bed to be boosted.

Before treatment plan designing, two planning target volumes (PTV<sub>breast</sub> and PTV<sub>boost</sub>) were generated from their respective CTVs using anisotropic margins: 3 mm anteriorly/laterally and 5 mm in other directions, followed by a 2 mm skin retraction. Over the cohort, the average volume of PTV<sub>breast</sub> and PTV<sub>boost</sub> (mean  $\pm$  standard deviation) was  $962.89 \pm 258.12$  cm<sup>3</sup>,  $112.87 \pm 51.41$  cm<sup>3</sup>, respectively.

To reduce PTV<sub>breast</sub> hot spots, we created a control structure named PTV<sub>b/b</sub>, which was defined as the region by subtracting PTV<sub>boost</sub> from PTV<sub>breast</sub> and then expanding by 1 cm isotopically. Meanwhile, axillary levels 1-3 regions (termed LNAxillaryLvI, LNAxillaryLvII, and LNAxillaryLvIII) were defined according to the anatomical structure.

### Treatment planning

**Target dose prescription:** The dose prescriptions for

CTV<sub>breast</sub> and CTV<sub>boost</sub> were 50 Gy/25 fractions and 60 Gy/25 fractions (simultaneously boost). The coverage requirements for CTV and PTV are  $D_{100\%} \geq 99\%$  and  $D_{100\%} \geq 95\%$ , respectively.

**IMRT and VMAT planning:** For each patient, treatment plans were designed using IMRT and VMAT techniques on the Eclipse (Version 15.6, Varian, Palo Alto, California, USA) treatment planning system, and delivered on a VitalBeam linear accelerator (Varian, Palo Alto, California, USA). The plan optimization utilized the PO (Progressive Optimization) engine enabling jaw tracking, and the dose calculation was performed using the AcurosXB algorithm.

**IMRT field setup:** For IMRT planning, all patients received 6 MV photon therapy. Since the target volumes of the left-sided breast cancer were close to the heart and left coronary artery, 4-5 fixed fields were employed to minimize cardiac dose, while 3-4 fixed fields were employed for patients with right-sided breast cancer. Please see Figure 1 for the beam arrangement.

**VMAT field setup:** All VMAT plans utilized 6 MV flattening filter-free beams with 4 partial-arc fields. For left-sided cases, arcs were positioned at: 179° counterclockwise (CCW)  $\rightarrow$  70°, 70° clockwise (CW)  $\rightarrow$  179°, 300° CW  $\rightarrow$  350°, and 350° CCW  $\rightarrow$  300°. Right-sided cases used: 181° CW  $\rightarrow$  290°, 290° CCW  $\rightarrow$  181°, 60° CCW  $\rightarrow$  10°, and 10° CW  $\rightarrow$  60° (please see Figure 2). The collimator Y-axis was aligned parallel to CTV<sub>breast</sub>'s long axis for optimal delivery. This arc arrangement ensured precise and efficient radiation delivery to the target volumes.




Figure 1. Treatment fields setup for IMRT plan. (A) Left-sided breast -IMRT; (B) Right-sided breast -IMRT.




Figure 2. Treatment fields setup for VMAT plan. (A) Left-sided breast -VMAT; (B) Right-sided breast -VMAT.

### Evaluation metrics

To identify the strengths and limitations of both treatment techniques, target coverage, dose distribution, and OAR sparing were compared. For the target,  $D_{100\%}$ ,  $D_{95\%}$ ,  $V_{107\%}$ ,  $D_{max}$ ,  $D_{mean}$ ,  $D_{min}$  and Conformity Index (CI) were calculated respectively.  $D_{100\%}$  means dose to 100% of the target volume.  $D_{95\%}$

means dose to 95% of the target volume.  $V_{107\%}$  means the volume receiving 107% of the prescribed dose.  $D_{max}$  means maximum dose,  $D_{mean}$  means average dose and  $D_{min}$  means minimum dose. Note that CI was defined as (20, 21):

$$CI = \frac{V_{PTV50}}{V_{PTV}} * \frac{V_{PTV}}{V_{50}} \quad (1)$$

In Equation (1),  $V_{PTV50}$  represented the volume of the PTV receiving the prescription dose (50 Gy),  $V_{PTV}$  denoted the PTV volume, and  $V_{50}$  referred to the total volume receiving the prescription dose (50 Gy). A CI value closer to 1 indicated better conformity.

For  $PTV_{b/b}$ ,  $V_{50\%}$ ,  $V_{54\%}$ , and  $V_{55\%}$  ( $V_x\%$  means the volume receiving x Gy) were calculated. We used  $V_5$ ,  $V_{20}$ ,  $V_{40}$ ,  $D_{max}$ , and  $D_{mean}$  to evaluate the OAR sparing. The monitor units (MU) of the IMRT and VMAT plans were also compared.

**Statistical analysis**

The statistical analysis was performed using SPSS 26.0. We first used Shapiro-Wilk and Kolmogorov-Smirnov tests to verify the data normality, with significance criteria set at 0.05, where  $p < 0.05$  indicates non-normality. Wilcoxon signed-rank test was then used to compare the, with a statistical significance threshold set at  $p < 0.05$ .

**RESULTS**

**DVH overview and representative cases**

Figure 3 compares the average dose-volume histograms (DVHs) between VMAT and IMRT, demonstrating significant dosimetric differences for both target volumes and OARs. Furthermore, representative cases in Figures 4-5 show VMAT's superior  $PTV_{breast}$  and axillary level conformity compared to IMRT. The DVH data of left- and right-sided patients were collected, the average values were calculated, and the graph was created. The solid line represents the IMRT plan, and the dashed line represents the VMAT plan (figure 3).




Figure 3. The average DVH for left- and right-sided breast cancer patients. (A) The average DVH of left-sided patients. (B) The average DVH of right-sided patients.

**Comparison of target volume doses CTV & PTV**

The evaluated DVH parameters of the target volumes included the  $D_{95\%}$ ,  $V_{107\%}$ ,  $D_{max}$ ,  $D_{mean}$ , and  $D_{min}$  for  $CTV_{breast}$ ,  $CTV_{boost}$ ,  $PTV_{breast}$ ,  $PTV_{boost}$ , and  $PTV_{b/b}$ , along with CI for  $PTV_{breast}$  and  $PTV_{boost}$ . Table 1

presents the target volumes dose comparison for left-sided breast cancer patients. VMAT demonstrated: (1) higher  $CTV_{breast} D_{100\%}$  and  $D_{min}$  but lower  $D_{mean}$  versus IMRT; (2) superior  $PTV_{breast} D_{95\%}$  meeting prescription requirements; (3) reduced  $V_{107\%}$  for both  $PTV_{breast}$  and  $PTV_{boost}$ ; (4) lower  $PTV_{b/b} V_{54}$  and  $V_{55}$  values; (5) improved CIs ( $PTV_{breast}$ : 0.79 vs 0.70;  $PTV_{boost}$ : 0.68 vs 0.59). These results confirm VMAT's dosimetric advantages in target coverage and conformity.




Figure 4. A representative case of a left-sided breast cancer patient. (A) Transverse plane dose of IMRT plan. (B) Transverse plane dose of VMAT plan.




Figure 5. A representative case of a right-sided breast cancer patient. (A) Transverse plane dose of IMRT plan. (B) Transverse plane dose of VMAT plan.

Table 2 presents the target volumes dose comparison for right-sided breast cancer patients. VMAT demonstrated: (1) lower  $CTV_{breast} D_{mean}$  but higher  $D_{100\%}$  and  $D_{min}$  compared to IMRT; (2) improved  $PTV_{breast}$  and  $PTV_{boost} D_{95\%}$ , meeting prescription requirements; (3) reduced  $PTV_{boost} V_{107\%}$  and  $PTV_{breast} D_{mean}$ ; (4) decreased  $PTV_{b/b} V_{54}$  and  $V_{55}$ ; (5) superior CIs ( $PTV_{breast}$ : 0.79 vs 0.71;  $PTV_{boost}$ : 0.70 vs 0.60). These findings further support VMAT's dosimetric advantages for right-sided cases.

**Table 1.** Dosimetric comparison of target volumes for left-sided breast cancer patients.

Structure	Metrics	IMRT		VMAT		p-value
		Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	
CTV <sub>breast</sub>	D <sub>100%</sub> (Gy)	42.87 ± 4.88	47.02 ± 1.66	<0.001		
	D <sub>max</sub> (Gy)	67.14 ± 1	67.3 ± 0.84	0.432		
	D <sub>mean</sub> (Gy)	56.09 ± 0.74	55.81 ± 0.69	0.002		
	D <sub>min</sub> (Gy)	42.86 ± 4.89	47.01 ± 1.66	<0.001		
CTV <sub>boost</sub>	D <sub>100%</sub> (Gy)	59.32 ± 1.16	59.46 ± 1.04	0.915		
	D <sub>max</sub> (Gy)	66.4 ± 0.95	66.46 ± 0.72	0.734		
	D <sub>mean</sub> (Gy)	63.39 ± 0.51	63.35 ± 0.33	0.592		
	D <sub>min</sub> (Gy)	59.32 ± 1.16	59.46 ± 1.04	0.915		
PTV <sub>breast</sub>	D <sub>95%</sub> (Gy)	49.68 ± 0.67	50.12 ± 0.11	0.001		
	V <sub>107%</sub> (%)	60.3 ± 5.54	57.9 ± 5.82	0.042		
	D <sub>max</sub> (Gy)	67.49 ± 1.03	67.39 ± 0.85	0.617		
	D <sub>mean</sub> (Gy)	55.12 ± 0.59	54.91 ± 0.54	0.024		
	D <sub>min</sub> (Gy)	20.83 ± 7.25	33.35 ± 4.52	<0.001		
	CI	0.7 ± 0.04	0.79 ± 0.03	<0.001		
PTV <sub>boost</sub>	D <sub>95%</sub> (Gy)	60.36 ± 0.48	60.4 ± 0.16	0.802		
	V <sub>107%</sub> (%)	18.96 ± 13.29	12.1 ± 8.22	0.014		
	D <sub>max</sub> (Gy)	67.01 ± 0.95	66.85 ± 0.67	0.352		
	D <sub>mean</sub> (Gy)	62.89 ± 0.42	62.83 ± 0.21	0.532		
	D <sub>min</sub> (Gy)	52.58 ± 2.96	53.12 ± 2.08	0.335		
	CI	0.59 ± 0.12	0.68 ± 0.1	0.001		
PTV <sub>b/b</sub>	V <sub>54</sub> (%)	41.34 ± 7.18	35.79 ± 6.69	0.001		
	V <sub>55</sub> (%)	24.74 ± 7.76	16.63 ± 6.33	<0.001		

\*Abbreviations: SD: standard deviation; Dmax: maximum dose; Dmean: average dose; Dmin: minimum dose; D100%: dose to 100% of the target volume; D95%: dose to 95% of the target volume; V107%: the volume receiving 107% of the prescribed dose; V54: the volume receiving 54 Gy; V55: the volume receiving 55 Gy; CI: Conformity Index.

**Table 2.** Dosimetric comparison of target volumes for right-sided breast cancer patients.

Structure	Metrics	IMRT		VMAT		p-value
		Mean	SD	Mean	SD	
CTV <sub>breast</sub>	D <sub>100%</sub> (Gy)	42.69	4.17	46.49	1.7	<0.001
	D <sub>max</sub> (Gy)	66.89	1.21	66.98	0.9	0.617
	D <sub>mean</sub> (Gy)	56.14	0.76	55.81	0.65	<0.001
	D <sub>min</sub> (Gy)	42.68	4.18	46.49	1.7	<0.001
CTV <sub>boost</sub>	D <sub>100%</sub> (Gy)	58.88	1.56	59.07	1.4	0.238
	D <sub>max</sub> (Gy)	66.25	1.17	66.39	0.71	0.195
	D <sub>mean</sub> (Gy)	63.29	0.55	63.21	0.27	0.567
	D <sub>min</sub> (Gy)	58.88	1.56	59.07	1.4	0.24
PTV <sub>breast</sub>	D <sub>95%</sub> (Gy)	49.61	0.61	50.15	0.18	<0.001
	V <sub>107%</sub> (%)	60.28	7.04	58.68	5.14	0.137
	D <sub>max</sub> (Gy)	67.11	1.22	67.07	0.85	0.956
	D <sub>mean</sub> (Gy)	55.12	0.67	54.94	0.53	0.009
	D <sub>min</sub> (Gy)	19.41	6.82	34.2	3.4	<0.001
	CI	0.71	0.05	0.79	0.03	<0.001
PTV <sub>boost</sub>	D <sub>95%</sub> (Gy)	60.23	0.32	60.36	0.2	<0.001
	V <sub>107%</sub> (%)	16.36	13.77	8.98	7.14	<0.001
	D <sub>max</sub> (Gy)	66.8	1.05	66.86	0.67	0.541
	D <sub>mean</sub> (Gy)	62.8	0.44	62.72	0.21	0.243
	D <sub>min</sub> (Gy)	52.68	2.15	52.57	2.21	0.617
	CI	0.6	0.09	0.7	0.07	<0.001
PTV <sub>b/b</sub>	V <sub>54</sub> (%)	40.56	9.43	35.02	6.54	0.001
	V <sub>55</sub> (%)	23.9	9.44	14.89	6.16	<0.001

\*Abbreviations: SD: standard deviation; Dmax: maximum dose; Dmean: average dose; Dmin: minimum dose; D100%: dose to 100% of the target volume; D95%: dose to 95% of the target volume; V107%: the volume receiving 107% of the prescribed dose; V54: the volume receiving 54 Gy; V55: the volume receiving 55 Gy; CI: Conformity Index.

**LNaxillaryLvl & II**

As axillary levels 1-2 are encompassed within CTV<sub>breast</sub>, their dosimetry was evaluated separately. Tables 3 and 4 demonstrate that for both left- and right-sided cases: (1) VMAT achieved comparable or superior V<sub>50</sub> and CI values versus IMRT; (2) VMAT showed higher D<sub>min</sub> for left-sided axillary levels 1-2; (3) VMAT consistently reduced D<sub>mean</sub> for right-sided axillary levels 1-2.

**Table 3.** Dosimetric comparison of LNaxillaryLvl & II for left-sided breast cancer patients.

Structure	Metrics	IMRT		VMAT		p-value
		Mean	SD	Mean	SD	
LNaxillaryLvl	V <sub>50</sub> (%)	99.00	0.98	99.48	0.52	0.027
	D <sub>max</sub> (Gy)	61.86	3.09	60.22	3.11	0.017
	D <sub>mean</sub> (Gy)	53.53	0.55	53.32	0.46	0.097
	D <sub>min</sub> (Gy)	45.12	4.20	47.85	1.78	<0.001
	CI	0.11	0.21	0.12	0.21	<0.001
LNaxillaryLvlII	V <sub>50</sub> (%)	99.05	1.45	99.76	0.56	0.04
	D <sub>max</sub> (Gy)	63.07	3.37	63.07	3.43	0.02
	D <sub>mean</sub> (Gy)	54.37	1.24	54.23	0.76	0.68
	D <sub>min</sub> (Gy)	48.01	2.38	48.95	1.83	0.03
	CI	0.04	0.01	0.04	0.01	<0.001

\*Abbreviations: LNaxillaryLvl: the axillary levels 1; LNaxillaryLvlII: the axillary levels 2; SD: standard deviation; Dmax: maximum dose; Dmean: average dose; Dmin: minimum dose; V50: the volume receiving 50 Gy; CI: Conformity Index.

**Table 4.** Dosimetric comparison of LNaxillaryLvl & II for right-sided breast cancer patients.

Structure	Parameter	IMRT		VMAT		p-value
		Mean	SD	Mean	SD	
LNaxillaryLvl	V <sub>50</sub> (%)	98.74	1.39	99.47	0.57	<0.001
	D <sub>max</sub> (Gy)	63.58	3.24	61.25	3.30	<0.001
	D <sub>mean</sub> (Gy)	53.76	0.87	53.41	0.70	0.001
	D <sub>min</sub> (Gy)	44.87	3.84	44.87	1.78	<0.001
	CI	0.10	0.02	0.11	0.02	<0.001
LNaxillaryLvlII	V <sub>50</sub> (%)	98.79	1.74	99.83	0.29	<0.001
	D <sub>max</sub> (Gy)	63.91	3.28	63.22	3.34	0.40
	D <sub>mean</sub> (Gy)	54.67	1.27	54.53	0.81	0.02
	D <sub>min</sub> (Gy)	47.83	2.43	48.27	2.25	0.348
	CI	0.04	0.01	0.05	0.13	<0.001

\*Abbreviations: LNaxillaryLvl: the axillary levels 1; LNaxillaryLvlII: the axillary levels 2; SD: standard deviation; Dmax: maximum dose; Dmean: average dose; Dmin: minimum dose; V50: the volume receiving 50 Gy; CI: Conformity Index.

**Comparison of OAR doses**

Table 5 summarizes heart and left coronary artery dose comparisons for left- and right-sided breast cancer patients. For left-sided patients, VMAT demonstrated: (1) reduced heart D<sub>mean</sub>; (2) significant left coronary artery D<sub>mean</sub> reduction (Δ9.51 Gy vs IMRT); (3) 33% decrease in left coronary artery V<sub>40</sub>. For right-sided patients, the D<sub>mean</sub> for the heart and left coronary artery slightly increases in the VMAT plan compared to the IMRT plan but remained within an acceptable range.

**Ipsilateral OARs**

Table 6 indicates that the D<sub>mean</sub> for ipsilateral humeral head and lung are reduced to varying degrees in the VMAT plan compared to the IMRT plan. For left-sided breast cancer patients, the D<sub>mean</sub> for the

ipsilateral humeral head and lung is reduced by 5.47 Gy and 1.2 Gy in the VMAT plan compared to the IMRT plan. The V<sub>20</sub>, V<sub>40</sub>, and V<sub>5</sub> for the ipsilateral lung decreased from 20.76%, 10.01%, and 40% in the IMRT plan to 18.12%, 6.78%, and 38.02% in the VMAT plan. For right-sided breast cancer patients, the D<sub>mean</sub> for the ipsilateral humeral head and lung is reduced by 4.36 Gy and 1.42 Gy in the VMAT plan compared to the IMRT plan. The V<sub>20</sub>, V<sub>40</sub>, and V<sub>5</sub> for the ipsilateral lung decreased from 20.94%, 10.96%, and 41.12% in the IMRT plan to 18.19%, 7.24%, and 37.93% in the VMAT plan. Importantly, there is no statistically significant difference in the dose of LNAxillaryLvIII between the VMAT and IMRT plans.

**Table 5.** Dosimetric comparison of heart and left coronary artery for left- and right-sided breast cancer patients.

Structure	Parameter	IMRT		VMAT		p-value
		Mean	SD	Mean	SD	
Heart_L	D <sub>mean</sub> (Gy)	4.21	1.5	3.48	1.07	<0.001
LAD_L	V <sub>40</sub> (%)	33.23	25.63	0.75	1.35	<0.001
	D <sub>mean</sub> (Gy)	26.32	9.36	16.97	5.71	<0.001
Heart_R	D <sub>mean</sub> (Gy)	0.77	0.19	1.47	0.3	<0.001
LAD_R	D <sub>mean</sub> (Gy)	0.48	0.15	2.24	0.72	<0.001

\*Abbreviations: Heart\_L: heart for left-sided breast cancer patients. LAD\_L: left coronary artery for left-sided breast cancer patients. Heart\_R: heart for right-sided breast cancer patients. LAD\_R: left coronary artery for right-sided breast cancer patients. SD: standard deviation; Dmax: maximum dose; Dmean: average dose; Dmin: minimum dose; V40: the volume receiving 40 Gy.

**Table 6.** Dosimetric comparison of ipsilateral OARs for breast cancer patients.

Structure	Parameter	IMRT		VMAT		p-value	
		Mean	SD	Mean	SD		
Left-sided	Ipsilateral GHJoint	D <sub>mean</sub> (Gy)	16.41	8.53	10.94	6.16	<0.001
	Ipsilateral Lung	V <sub>20</sub> (%)	20.76	2.24	18.12	2.35	<0.001
		V <sub>40</sub> (%)	10.01	2.62	6.78	1.51	<0.001
		V <sub>5</sub> (%)	40	4	38.02	3.9	<0.001
		D <sub>mean</sub> (Gy)	11.05	0.99	9.85	0.89	<0.001
LNAxillaryLvIII	D <sub>max</sub> (Gy)	56.84	1.98	56.41	1.48	0.29	
	D <sub>mean</sub> (Gy)	46.81	6.42	45.54	4.34	0.28	
Right-sided	Ipsilateral GHJoint	D <sub>mean</sub> (Gy)	15.27	6.62	10.91	4.92	<0.001
	Ipsilateral Lung	V <sub>20</sub> (%)	20.94	2.17	18.19	2.17	<0.001
		V <sub>40</sub> (%)	10.96	2.07	7.24	1.52	<0.001
		V <sub>5</sub> (%)	41.12	3.88	37.93	3.36	<0.001
		D <sub>mean</sub> (Gy)	11.37	1.05	9.95	0.89	<0.001
	LNAxillaryLvIII	D <sub>max</sub> (Gy)	55.86	2.27	56.11	1.36	0.49
D <sub>mean</sub> (Gy)		46.22	5.22	46.94	5.14	0.09	

\* Abbreviations: LNAxillaryLvIII: the axillary levels 3; SD: standard deviation; Dmax: maximum dose; Dmean: average dose; Dmin: minimum dose; V20: the volume receiving 20 Gy; V40: the volume receiving 40 Gy; V5: the volume receiving 5 Gy.

**Contralateral OARs**

Table 7 demonstrates that the D<sub>max</sub>/D<sub>mean</sub> for the contralateral breast and D<sub>mean</sub> for the contralateral lung slightly increased in the VMAT plan compared to the IMRT plan but remained within an acceptable range.

**Comparison of MU values**

For left-sided patients, the MU values are 1089.15 ± 262 (p < 0.01) and 840.73 ± 49.25 (p < 0.01) for IMRT and VMAT plans. For right-sided patients, the

MU values are 1008.38 ± 220.85 (p < 0.01) and 839.98 ± 31.07 (p < 0.01) for IMRT and VMAT plans. The result indicates that the MU values are higher for the IMRT plan than the VMAT plan, and there are more significant variations in the IMRT plan.

**Table 7.** Dosimetric comparison of contralateral OARs for breast cancer patients.

	Structure	Parameter	IMRT		VMAT		p-value
			Mean	SD	Mean	SD	
Left-sided	Contralateral Breast	D <sub>max</sub> (Gy)	18.92	13.44	23.61	9.64	0.026
		D <sub>mean</sub> (Gy)	0.64	0.27	2.53	0.8	<0.001
	Contralateral Lung	D <sub>mean</sub> (Gy)	0.35	0.09	0.96	0.17	<0.001
Right-sided	Contralateral Breast	D <sub>max</sub> (Gy)	15.55	9.68	22.73	8.1	<0.001
		D <sub>mean</sub> (Gy)	0.64	0.3	2.39	0.74	<0.001
	Contralateral Lung	D <sub>mean</sub> (Gy)	0.29	0.04	0.81	0.19	<0.001

**DISCUSSION**

Radiotherapy is widely used for breast-conserving surgery patients with 1-2 sentinel lymph node metastases, demonstrating comparable efficacy to surgical intervention with fewer side effects (22). The National Comprehensive Cancer Network (NCCN) guidelines (23) recommend whole-breast tangential IMRT for this patient case. However, the expanded target volume limits this technique's ability to achieve optimal dose conformity and distribution. This study evaluated the clinical benefits of partial-arc (four-field) VMAT versus conventional tangential IMRT in breast-conserving surgery patients with 1-2 sentinel lymph node metastases. Results demonstrated VMAT's superior prescription dose conformity, enhanced target coverage, and improved organ-at-risk sparing compared to IMRT.

For both left- and right-sided breast cancers, VMAT demonstrated superior target coverage compared to IMRT, as evidenced by higher D<sub>95%</sub> values for both PTV<sub>breast</sub> and PTV<sub>boost</sub>, and improved V<sub>50</sub> coverage of axillary levels 1-2. While IMRT often failed to achieve the prescription dose, these findings highlight VMAT's advantage in ensuring optimal dose delivery to target volumes.

VMAT plan also demonstrated better conformity indices (CIs) for PTV<sub>breast</sub>, PTV<sub>boost</sub>, and axillary levels 1-2 compared to IMRT. A higher CI indicated better dose conformity (20, 21). Notably, VMAT also achieved significantly lower high-dose volumes (V<sub>54</sub>/V<sub>55</sub> for PTV<sub>b/b</sub>; V<sub>107%</sub> for PTV<sub>breast/boost</sub>, p < 0.05), indicating reduced high-dose spillage. These improvements may decreased risks of early edema and late fibrosis (24), while aligning with established VMAT advantages in breast radiotherapy (25-27).

Consistent with previous research (13, 18, 28, 29), VMAT significantly reduced dose to OARs in this study. For left-sided cases, VMAT lowered heart and left coronary artery exposure, while all cases demonstrated reduced ipsilateral lung and humeral

head doses. These dosimetric advantages might decrease radiation-induced complications (e.g., pneumonitis) and potentially reduce secondary radiotherapy risks (30, 31). Although VMAT increased contralateral breast/lung doses slightly, these doses remained within acceptable limits (18, 29, 32-34).

Although utilizing a similar number of fields, VMAT demonstrated significantly lower monitor unit (MU) requirements than IMRT (35-37). This reduction offered two key advantages: (1) simplified treatment planning through fewer segments, potentially enhancing delivery efficiency and accuracy (38, 39); and (2) shorter treatment times, which might minimize target displacement risks from intrafraction motion.

For partial-arc fields, minor adjustments to arc angles might be clinically implemented based on target location and plan complexity, aiming to optimize target coverage while sparing surrounding healthy tissues. A limitation of this study was its focus on a specific case type; future research would investigate VMAT applications for other breast cancer scenarios.

## CONCLUSIONS

This study demonstrates that VMAT is a reliable and effective radiotherapy technique for breast-conserving surgery patients with 1-2 sentinel lymph node metastases. Although VMAT may result in slightly higher doses to certain OARs compared to IMRT, treatment selection should be individualized based on target location, OAR considerations, and planning complexity.

**Acknowledgment:** This study was partially supported by the National Natural Science Foundation of China (No. 12375335 and 12005007), the Beijing Natural Science Foundation (No. 1212011), and the Science Foundation of Peking University Cancer Hospital (No. ZY202410).

**Conflict of interest:** The authors declare that they have no conflict of interest to disclose.

**Authors' contribution:** All authors had made significant contributions in experimental design, data collection, and analysis, as well as ensuring the scientific and reliable nature of the research.

**Declaration of AI usage:** The manuscript has been proof-read using large language model (DeepSeek-R1) to improve the content clarity and to correct grammar errors. After the AI-based proof-reading, the authors have carefully re-proofed the whole manuscript, and the authors are fully responsible for the originality of this manuscript.

## REFERENCES

1. Fakhri N, Chad MA, Lahkim M, Houari A, Dehbi H, Belmouden A, *et al.* (2022) Risk factors for breast cancer in women: an update review. *Med Oncol*, **39**(12): 197.

2. Bartels SAL, Donker M, Poncet C, Sauve N, Straver ME, van de Velde CJH, *et al.* (2023) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS Trial. *J Clin Oncol*, **41**(12): 2159-65.
3. Garcia-Etienne CA, Ferrari A, Della Valle A, Lucioni M, Ferraris E, Di Giulio G, *et al.* (2020) Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center. *Eur J Surg Oncol*, **46**(1): 15-23.
4. Jimenez-Gomez M, Loro-Perez J, Vega-Benitez V, Hernandez-Hernandez JR, Aguirre NA (2023) Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up. *J Cancer Res Ther*, **19**(2): 183-90.
5. Ling DC, Larrobino NA, Champ CE, Soran A, Beriwal S (2020) Regional recurrence rates with or without complete axillary dissection for breast cancer patients with node-positive disease on sentinel lymph node biopsy after neoadjuvant chemotherapy. *Adv Radiat Oncol*, **5**(2): 163-70.
6. Wu J, Lu AD, Zhang LP, Zuo YX, Jia YP (2019) Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia. *Zhonghua Xue Ye Xue Za Zhi*, **40**(1): 52-7.
7. Reed DR, Lindsley SK, Mann GN, Austin-Seymour M, Korssjoen T, Anderson BO, *et al.* (2005) Axillary lymph node dose with tangential breast irradiation. *Int J Radiat Oncol Biol Phys*, **61**(2): 358-64.
8. Jacobson G, Bunda-Randall N, Wen S, Miller M (2017) Axillary lymph node coverage with 3-dimensional tangential field irradiation and correlation with heart and lung dose. *Adv Radiat Oncol*, **2**(4): 630-5.
9. Nitsche M, Temme N, Forster M, Reible M, Hermann RM (2014) Tangential vs defined radiotherapy in early breast cancer treatment without axillary lymph node dissection: a comparative study. *Strahlenther Onkol*, **190**(8): 715-21.
10. Alco G, Igdem SI, Ercan T, Dincer M, Senturk R, Atilla S, *et al.* (2010) Coverage of axillary lymph nodes with high tangential fields in breast radiotherapy. *Br J Radiol*, **83**(996): 1072-6.
11. Seppala J, Heikkila J, Myllyoja K, Koskela K (2015) Volumetric modulated arc therapy for synchronous bilateral whole breast irradiation - A case study. *Rep Pract Oncol Radiother*, **20**(5): 398-402.
12. Bi S, Zhu R, Dai Z (2022) Dosimetric and radiobiological comparison of simultaneous integrated boost radiotherapy for early stage right side breast cancer between three techniques: IMRT, hybrid IMRT and hybrid VMAT. *Radiat Oncol*, **17**(1): 60.
13. Rossi M, Boman E, Kapanen M (2019) Contralateral tissue sparing in lymph node-positive breast cancer radiotherapy with VMAT technique. *Med Dosim*, **44**(2): 117-21.
14. Shao WC, Yin HT, Zhang H. (2022) Assessment of vital organ dose in volumetric intensity modulated arc therapy for left and right breast cancer. *Int J Radiat Res*, **20**(4): 761-5.
15. Arslan A, Aktas E, Eren SK, Dengiz I, Arslan SA, Güney Y (2023) Dosimetric comparison of the heart substructures with IMRT and VMAT techniques in left breast radiotherapy: The effect of deep inspiratory breath-hold. *Int J Radiat Res*, **21**(1): 23-30.
16. Viren T, Heikkila J, Myllyoja K, Koskela K, Lahtinen T, Seppala J (2015) Tangential volumetric modulated arc therapy technique for left-sided breast cancer radiotherapy. *Radiat Oncol*, **10**: 79.
17. Byrne M, Archibald-Heeren B, Hu Y, Fong A, Chong L, Teh A (2018) Comparison of semiautomated tangential VMAT with 3DCRT for breast or chest wall and regional nodes. *J Appl Clin Med Phys*, **19**(5): 684-93.
18. Boman E, Rossi M, Haltamo M, Skytta T, Kapanen M (2016) A new split arc VMAT technique for lymph node positive breast cancer. *Phys Med*, **28**: s1120-1797 (16) 30954-1.
19. Offersens BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, *et al.* (2015) ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. *Radiother Oncol*, **114**(1): 3-10.
20. Paddick I and Lippitz B (2006) A simple dose gradient measurement tool to complement the conformity index. *J Neurosurg*, **105** Suppl: 194-201.
21. Shaw E, Kline R, Gillin M, Souhami L, Hirschfeld A, Dinapoli R, *et al.* (1993) Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. *Int J Radiat Oncol Biol Phys*, **27**(5): 1231-9.
22. Castelo M, Hu SY, Dossa F, Acuna SA, Scheer AS (2020) Comparing observation, axillary radiotherapy, and completion axillary lymph node dissection for management of axilla in breast cancer in

- patients with positive sentinel nodes: A systematic review. *Ann Surg Oncol*, **27**(8): 2664-76.
23. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. (2023) NCCN Guidelines(R) Insights: Breast Cancer, Version 4.2023. *J Natl Compr Canc Netw*, **21**(6): 594-608.
  24. Keenan LG, Lavan N, Dunne M, McArdle O (2019) Modifiable risk factors for acute skin toxicity in adjuvant breast radiotherapy: Dosimetric analysis and review of the literature. *Med Dosim*, **44**(1): 51-5.
  25. Qiu J, Zhang S, Lv B, Zheng X (2021) Cardiac dose control and optimization strategy for left breast cancer radiotherapy with non-uniform VMAT technology. *Technol Cancer Res Treat*, **20**: 15330338211053752.
  26. Liu ZM, Ge XL, Chen JY, Wang PP, Zhang C, Yang X, et al. (2015) Adjuvant radiotherapy after breast conserving treatment for breast cancer: a dosimetric comparison between volumetric modulated arc therapy and intensity modulated radiotherapy. *Asian Pac J Cancer Prev*, **16**(8): 3257-65.
  27. Zhang Q, Yu XL, Hu WG, Chen JY, Wang JZ, Ye JS, et al. (2015) Dosimetric comparison for volumetric modulated arc therapy and intensity-modulated radiotherapy on the left-sided chest wall and internal mammary nodes irradiation in treating post-mastectomy breast cancer. *Radiol Oncol*, **49**(1): 91-8.
  28. Xie Y, Bourgeois D, Guo B, Zhang R (2020) Postmastectomy radiotherapy for left-sided breast cancer patients: Comparison of advanced techniques. *Med Dosim*, **45**(1): 34-40.
  29. Popescu CC, Olivetto IA, Beckham WA, Ansbacher W, Zavgorodni S, Shaffer R, et al. (2010) Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes. *Int J Radiat Oncol Biol Phys*, **76**(1): 287-95.
  30. Seo I and Jang H (2022) Increased second primary liver cancer risk in young breast cancer patients undergoing radiotherapy and chemotherapy: a nationwide population-based study. *Int J Radiat Res*, **20**(2): 291-7.
  31. Jang H, Baek JG, Kim W, Sohn JH (2021) Assessment of intensity modulated radiation therapy in left breast cancer including regional nodes without the internal mammary node: secondary cancer risks on thyroid and stomach. *Int J Radiat Res*, **19**(4): 921-8.
  32. Abo-Madyan Y, Aziz MH, Aly MM, Schneider F, Sperk E, Clausen S, et al. (2014) Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer. *Radiother Oncol*, **110**(3): 471-6.
  33. Lee B, Lee S, Sung J, Yoon M (2014) Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT. *J Radiol Prot*, **34**(2): 325-31.
  34. Fogliata A, De Rose F, Franceschini D, Stravato A, Seppala J, Scorsetti M, et al. (2018) Critical appraisal of the risk of secondary cancer induction from breast radiation therapy with volumetric modulated arc therapy relative to 3D conformal therapy. *Int J Radiat Oncol Biol Phys*, **100**(3): 785-93.
  35. Yin Y, Chen J, Sun T, Ma C, Lu J, Liu T, et al. (2012) Dosimetric research on intensity-modulated arc radiotherapy planning for left breast cancer after breast-preservation surgery. *Med Dosim*, **37**(3): 287-92.
  36. Tsai PF, Lin SM, Lee SH, Yeh CY, Huang YT, Lee CC, et al. (2012) The feasibility study of using multiple partial volumetric-modulated arcs therapy in early stage left-sided breast cancer patients. *J Appl Clin Med Phys*, **13**(5): 3806.
  37. Liu H, Chen X, He Z, Li J. (2016) Evaluation of 3D-CRT, IMRT and VMAT radiotherapy plans for left breast cancer based on clinical dosimetric study. *Comput Med Imaging Graph*, **54**: 1-5.
  38. Chun M, Joon An H, Kwon O, Oh DH, Park JM, Kim JI (2019) Impact of plan parameters and modulation indices on patient-specific QA results for standard and stereotactic VMAT. *Phys Med*, **62**: 83-94.
  39. Park JM, Kim JI, Park SY (2019) Modulation indices and plan delivery accuracy of volumetric modulated arc therapy. *J Appl Clin Med Phys*, **20**(6): 12-22.

